Intraoperative Use of Low-Dose Recombinant Activated Factor VII During Thoracic Aortic Operations
نویسندگان
چکیده
منابع مشابه
Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass.
Postoperative bleeding is a common complication following cardiothoracic surgical procedures requiring cardiopulmonary bypass (CPB). Serious bleeding complications requiring the administration of blood products, hemostatic drugs, and even repeat surgery are associated with considerable morbidity, mortality, and resource consumption. Therapy with recombinant activated factor VII (rFVIIa) may be ...
متن کاملUse of recombinant activated factor VII in trauma
In this article we describe the current use of recombinant activated factor VII (rFVIIa; NovoSeven®) in trauma patients. Emphasis is placed on current uses as defined by key studies, efficacy data, and safety data. Most published studies in trauma patients are retrospective case studies and reports, although an international, double-blind, randomized, controlled, phase II study has been conduct...
متن کاملComparison of low- and high-dose recombinant activated factor VII for postcardiac surgical bleeding
AIM OF THE STUDY A retrospective observational study to compare safety and efficacy of high and low doses of recombinant activated factor VIIa (rFVIIa) in severe postcardiac surgical bleeding. PATIENTS AND METHODS From 2004 to 2014, all patients who received rFVIIa for bleeding after cardiac surgery were included and arranged in two groups; Group 1: Low dose (40-50 mcg/kg) (n = 98) and Group ...
متن کاملOff-Label Use of Recombinant Activated Factor VII (NovoSeven®)
NovoSeven® (Novo Nordisk, Denmark) is a recombinant DNA preparation of activated blood coagulation factor VII (rFVIIa). It is used to manage bleeding in hemophilia patients for whom standard therapy is inadequate because of the presence of inhibitors to either factor VIII (hemophilia A) or factor IX (hemophilia B). It poses no risk for the transmission of human pathogens, and it is infused in r...
متن کاملCombination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations
BACKGROUND Refractory blood loss is a common problem in surgeries for acute type A aortic dissections. Significant evidence has supported the benefit of using recombinant activated factor VII (rFVIIa) to control of intractable bleeding in patients after cardiac surgery. In this prospective clinical study, we present a novel method to achieve intraoperative hemostasis by using a combination of p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Annals of Thoracic Surgery
سال: 2012
ISSN: 0003-4975
DOI: 10.1016/j.athoracsur.2012.02.037